BeyondSpring Inc.

BYSI ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Revenue $0 $0 $0 $0 $0 $0 $0 $0
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $973.0K $1.1M $1.5M $1.0M $1.0M $874.0K $472.0K $622.0K
SG&A Expense $758.0K $1.2M $1.1M $751.0K $947.0K $1.7M $1.2M $1.7M
Operating Income $-1.7M $-2.2M $-2.6M $-1.8M $-1.9M $-2.6M $-1.7M $-2.4M
Operating Margin
Interest Expense
Pretax Income $-1.7M $-2.2M $-2.5M $-1.7M $-1.9M $-2.6M $-1.8M $-2.2M
Income Tax Expense $100.0K $192.0K $22.0K $26.0K $22.0K $20.0K $96.0K $0
Net Income $-849.0K $-2.2M $-2.1M $-1.5M $-1.8M $4.5M $-1.7M $-2.1M
Net Margin
EPS (Basic) $-0.02 $-0.05 $-0.05 $-0.04 $-0.04 $0.11 $-0.05 $-0.05
EPS (Diluted) $-0.02 $-0.10
Shares Outstanding (Basic) 41.1M 41.1M 41.1M 40.3M 40.3M 40.3M 40.3M 40.3M
Shares Outstanding (Diluted) 41.1M 41.1M 41.1M 40.3M 40.3M 40.3M 40.3M 40.3M
Dividends Per Share
← Newer Page 1 of 2 Older →